BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 748791)

  • 1. Lymphocyte-mediated cytotoxicity in patients with renal and transitional cell carcinoma receiving BCG.
    Lange PH
    Natl Cancer Inst Monogr; 1978 Dec; (49):343-5. PubMed ID: 748791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Classification of the bladder cancer patient based on in vitro measurements of the immune response.
    Lange PH; Hakala TR; Fraley EE
    Cancer Res; 1977 Aug; 37(8 Pt 2):2885-90. PubMed ID: 326395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transitional cell and renal carcinoma: cell-mediated immunity as determined by the lymphocyte titration technique.
    Hakala TR
    Natl Cancer Inst Monogr; 1978 Dec; (49):151-2. PubMed ID: 571043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody induction of lymphocyte-mediated cytotoxicity against human transitional-cell carcinomas of the urinary tract.
    Hakala TR; Lange PH; Castro AE; Elliott AY; Fraley EE
    N Engl J Med; 1974 Sep; 291(13):637-41. PubMed ID: 4859212
    [No Abstract]   [Full Text] [Related]  

  • 5. Correlation of primary tumor bed lymphocytic infiltration and peripheral lymphocyte cytotoxicity in patients with transitional cell carcinoma.
    Jones LW; O'Toole C
    Natl Cancer Inst Monogr; 1978 Dec; (49):183-5. PubMed ID: 748770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunocompetence and immunotherapy of patients with cancer of the kidney and bladder].
    Mokhort VA; Grigorovich NA; Strotskiĭ AV; Mavrichev AS
    Urol Nefrol (Mosk); 1986; (1):66-74. PubMed ID: 3513423
    [No Abstract]   [Full Text] [Related]  

  • 7. Transitional cell carcinoma: lymphocyte-mediated cytotoxicity.
    Troye M; Pape GR
    Natl Cancer Inst Monogr; 1978 Dec; (49):85-7. PubMed ID: 311895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphocyte antibody interaction in cytotoxicity against human transitional cell carcinoma.
    Hakala TR; Lange PH; Castro AE; Elliott AY; Fraley EE
    J Urol; 1975 May; 113(5):663-7. PubMed ID: 1168732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of BCG immunotherapy on cell-mediated cytotoxicity in bladder cancer patients following surgical treatment.
    Antonaci S; Piccinno A; Lucivero G; Miglietta A; Piccininno A; Bonomo L
    Tumori; 1981; 67(3):177-82. PubMed ID: 6974423
    [No Abstract]   [Full Text] [Related]  

  • 10. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.
    de Reijke TM; de Boer EC; Kurth KH; Schamhart DH
    J Urol; 1996 Feb; 155(2):477-82. PubMed ID: 8558640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies of the immunological effects of interleukin-2 in patients with bladder cancer and renal cell carcinoma.
    Hermann GG
    APMIS Suppl; 1993; 35():1-26. PubMed ID: 8251200
    [No Abstract]   [Full Text] [Related]  

  • 12. Carcinoma of the bladder.
    Lamm DL
    Tex Med; 1985 Feb; 81(2):32-4. PubMed ID: 3983864
    [No Abstract]   [Full Text] [Related]  

  • 13. In vitro immune parameters in relation to clinical course in transitional cell carcinoma.
    Cummings KB; Kodera Y; Bean MA
    Natl Cancer Inst Monogr; 1978 Dec; (49):119-22. PubMed ID: 155220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Follow-up of the effect of BCG vaccine treatment in bladder tumour patients.
    Kulcsár G; Nász I; Tenke P; Csata S
    Acta Microbiol Hung; 1993; 40(2):151-7. PubMed ID: 8184669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serial urinary IL-2, IL-6, IL-8, TNFalpha, UBC, CYFRA 21-1 and NMP22 during follow-up of patients with bladder cancer receiving intravesical BCG.
    Sanchez-Carbayo M; Urrutia M; Romani R; Herrero M; Gonzalez de Buitrago JM; Navajo JA
    Anticancer Res; 2001; 21(4B):3041-7. PubMed ID: 11712808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-associated and spontaneous lymphocyte-mediated cytotoxicity against cell lines derived from human urothelium.
    Vilien M
    Dan Med Bull; 1985 Aug; 32(4):199-218. PubMed ID: 3899526
    [No Abstract]   [Full Text] [Related]  

  • 17. [Adjuvant local BCG-immunotherapy in patients with urothel cancer of the bladder (author's transl)].
    Flamm J; Grof F
    Wien Med Wochenschr; 1981 Oct; 131(20):501-6. PubMed ID: 7314632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of bacillus Calmette-Guerin on cytotoxic activities of peripheral blood lymphocytes against human T24 lined and freshly isolated autologous urinary bladder transitional carcinoma cells in patients with urinary bladder cancer.
    Mizutani Y; Nio Y; Fukumoto M; Yoshida O
    Cancer; 1992 Jan; 69(2):537-45. PubMed ID: 1728384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of natural, interleukin-2 stimulated and bacillus Calmette-Guerin enhanced cytotoxicity with anti-CD16 antibodies.
    Kaasinen ES; Harju LM; Timonen TT
    J Urol; 2002 May; 167(5):2209-14. PubMed ID: 11956480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perforin-mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmette-Guérin-activated killer cells.
    Brandau S; Suttmann H; Riemensberger J; Seitzer U; Arnold J; Durek C; Jocham D; Flad HD; Böhle A
    Clin Cancer Res; 2000 Sep; 6(9):3729-38. PubMed ID: 10999767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.